Amneal Intermediate, Inc. (AMRX)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Company performance

Current Price

as of Dec 27, 2024

$7.82

P/E Ratio

N/A

Market Cap

$2.42B

Jan 9, 2024Feb 13, 2024Mar 19, 2024Apr 23, 2024May 29, 2024Jul 2, 2024Aug 2, 2024Sep 5, 2024Oct 8, 2024Nov 11, 2024Dec 27, 2024$0.00$10.00
  • AMRX
Description

Amneal Intermediate, Inc. is a pharmaceutical company, which engages in the development, manufacture, market and distribution of generic pharmaceutical products. It operates through the Generic, Specialty and AvKARE Segments. The Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products and transdermals. The Specialty segment provides proprietary medicines to the U.S. market. The AvKARE segment focuses on pharmaceuticals, medical and surgical products, and services primarily to governmental agencies. The company was founded by Chintu Patel and Chirag Patel in 2002 and is headquartered in Bridgewater, NJ.

Metrics

Overview

  • HQBridgewater, NJ
  • SectorHealth Technology
  • IndustryPharmaceuticals: Major
  • TickerAMRX
  • Price$7.82-0.38%

Trading Information

  • Market cap$2.42B
  • Float40.89%
  • Average Daily Volume (1m)1,124,657
  • Average Daily Volume (3m)1,048,635
  • EPS-$0.68

Company

  • Revenue$2.68B
  • Rev growth (1yr)13.29%
  • Net income-$0.16M
  • Gross margin38.37%
  • EBITDA margin21.17%
  • EBITDA$148.73M
  • EV$5.20B
  • EV/Revenue1.94
  • P/EN/A
  • P/S0.90
  • P/BN/A
Documents